相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Dual Monoclonal Antibody Therapy in Patients With Systemic AL Amyloidosis and Cardiac Involvement
Amandeep Godara et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)
Daratumumab proves safe and highly effective in AL amyloidosis
Jack Khouri et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment-resistant Immunoglobulin Light Chain Amyloidosis With Multiple Myeloma
Shumaila Muhammad Iqbal et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis
Jithma P. Abeykoon et al.
LEUKEMIA (2019)
The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
Laura Moreno et al.
CLINICAL CANCER RESEARCH (2019)
Venetoclax plus daratumumab induce hematological CR and organ response in an AL amyloidosis patient with t(11;14)
Guido Ghilardi et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2019)
One year follow up analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis
Camille V. Edwards et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2019)
Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis
Duncan B. Richards et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets
Carlos Cuesta-Mateos et al.
FRONTIERS IN IMMUNOLOGY (2018)
CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma-Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance
Anja Seckinger et al.
FRONTIERS IN IMMUNOLOGY (2018)
European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias
Maria Gavriatopoulou et al.
LEUKEMIA (2018)
Bifunctional amyloid-reactive peptide promotes binding of antibody 11-1F4 to diverse amyloid types and enhances therapeutic efficacy
Jonathan S. Wall et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis
Surbhi Sidana et al.
BONE MARROW TRANSPLANTATION (2018)
Real world data of the impact of first cycle daratumumab on multiple myeloma and AL amyloidosis services
Rakesh Popat et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Safety, Tolerability and Response Rates of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Results of a Phase II Study
Vaishali Sanchorawala et al.
BLOOD (2018)
Treatment with AMG 420, an Anti-B-Cell Maturation Antigen (BCMA) Bispecific T-Cell Engager (BiTE®) Antibody Construct, Induces Minimal Residual Disease (MRD) Negative Complete Responses in Relapsed and/or Refractory (R/R) Multiple Myeloma (MM) Patients: Results of a First-in-Human (FIH) Phase I Dose Escalation Study
Max S. Topp et al.
BLOOD (2018)
Seeking AL Amyloidosis Very Lady: The SAVF Trial - Identifying Clonal Lambda Light Chain Genes in Patients with MGUS or Smoldering Multiple Myeloma
Ping Zhou et al.
BLOOD (2018)
Improvement in Global Longitudinal Strain (GLS) Correlates with NT-Probnp Response in Patients with Cardiac Amyloidosis Treated on a Phase 1b Study of Anti-Amyloid Mab Cael-101
Divaya Bhutani et al.
BLOOD (2018)
Personalizing Amyloidosis Therapy with Real Time PET Imaging of Fibril-Reactive Monoclonal Antibody Cael-101
Jing Fu et al.
BLOOD (2018)
Efficacy and Safety of Daratumumab in a Frail Real-Life Relapsed or Refractory Systemic Light-Chain Amyloidosis Population (AL): Report on 15 Cases from the North of France
Zoe Van De Wyngaert et al.
BLOOD (2018)
Novel Therapies in Light Chain Amyloidosis
Paolo Milani et al.
KIDNEY INTERNATIONAL REPORTS (2018)
Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity
T. Jelinek et al.
HEMATOLOGICAL ONCOLOGY (2017)
Emerging therapeutic targets currently under investigation for the treatment of systemic amyloidosis
Mario Nuvolone et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2017)
Current applications of multiparameter flow cytometry in plasma cell disorders
T. Jelinek et al.
BLOOD CANCER JOURNAL (2017)
Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis
Gregory P. Kaufman et al.
BLOOD (2017)
Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma
Xiaoyan Feng et al.
CLINICAL CANCER RESEARCH (2017)
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis
Vaishali Sanchorawala et al.
BLOOD (2017)
A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma
Thomas Martin et al.
BLOOD (2017)
Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death
Eli Muchtar et al.
BLOOD (2017)
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis
Giovanni Palladini et al.
BLOOD (2017)
2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis
Mark Renz et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2016)
First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis
Taimur Sher et al.
BLOOD (2016)
What is new in diagnosis and management of light chain amyloidosis?
Giovanni Palladini et al.
BLOOD (2016)
Monoclonal antibodies - A new era in the treatment of multiple myeloma
Tomas Jelinek et al.
BLOOD REVIEWS (2016)
Immunomodulatory drugs in AL amyloidosis
T. Jelinek et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Monoclonal antibodies targeting CD38 in hematological malignancies and beyond
Niels W. C. J. van de Donk et al.
IMMUNOLOGICAL REVIEWS (2016)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The VITAL Amyloidosis Study: A Randomized, Double-Blind, Placebo-Controlled, Global, Phase 3 Study of NEOD001 in Patients with AL Amyloidosis and Cardiac Dysfunction
Michaela Liedtke et al.
BLOOD (2016)
NEOD001 Demonstrates Organ Biomarker Responses in Patients with Light Chain Amyloidosis and Persistent Organ Dysfunction: Results from the Expansion Cohort of a Phase 1/2 Study
Morie A. Gertz et al.
BLOOD (2016)
Organ Biomarker Responses in Patients with Light Chain Amyloidosis Treated with NEOD001 Are Independent of Previous Hematologic Response
Michaela Liedtke et al.
BLOOD (2016)
Analysis of the Phase 1a/b Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with AL Amyloidosis
Camille V. Edwards et al.
BLOOD (2016)
A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis
Efstathios Kastritis et al.
BLOOD (2016)
Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience
Vaishali Sanchorawala et al.
BLOOD (2015)
A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis
Giovanni Palladini et al.
BLOOD (2015)
Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study
Anita D'Souza et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Translocation t(11;14) Is Associated With Adverse Outcome in Patients With Newly Diagnosed AL Amyloidosis When Treated With Bortezomib-Based Regimens
Tilmann Bochtler et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement
Angela Dispenzieri et al.
MAYO CLINIC PROCEEDINGS (2015)
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Sagar Lonial et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component
Duncan B. Richards et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone
Tilmann Bochtler et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2014)
SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies
Jutta Deckert et al.
CLINICAL CANCER RESEARCH (2014)
Systemic light chain amyloidosis: an update for treating physicians
Giampaolo Merlini et al.
BLOOD (2013)
Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements
Shaji Kumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
AL Amyloid Imaging and Therapy with a Monoclonal Antibody to a Cryptic Epitope on Amyloid Fibrils
Jonathan S. Wall et al.
PLOS ONE (2012)
Radioimmunodetection of amyloid deposits in patients with AL amyloidosis
Jonathan S. Wall et al.
BLOOD (2010)
Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis
Julian D. Gillmore et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Antibodies to human serum amyloid P component eliminate visceral amyloid deposits
Karl Bodin et al.
NATURE (2010)
Localization of a conformational epitope common to non-native and fibrillar immunoglobulin light chains
Brian O'Nuallain et al.
BIOCHEMISTRY (2007)
Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis
V Sanchorawala et al.
BONE MARROW TRANSPLANTATION (2005)
Antibody-mediated resolution of light chain-associated amyloid deposits
R Hrncic et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
分享论文
